Eupraxia
Business Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2198 Yukon St, Vancouver, British Columb...Phone Number
(250) 590-3968Website
www.eupraxiapharma.comRevenue
-Stock Symbol
EPRXIndustry
About Eupraxia
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc.Explore more
Eupraxia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Eupraxia
Compare insights from companies similar to Eupraxia, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Eupraxia Tech Stack
A closer look at the technologies used by Eupraxia
See more technologies
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eupraxia
Sign Up For FreeTo access detailed company insights
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-... Read More
